Share this video  

VJVirtual | ANNOUNCE: doxorubicin + olaratumab in advanced soft tissue sarcomas

Robin Jones • 28 Apr 2020
Sarcoma Doxorubicin Olaratumab

Robin Jones, MBBS, MRCP, MD (Res), Royal Marsden NHS Foundation Trust, London, UK, updates us on recent results published from the ANNOUNCE Phase III study which evaluated the addition of olaratumab to doxorubicin in patients with advanced/metastatic soft tissue sarcoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Robin Jones

1:13
APROMISS: anlotinib versus dacarbazine in advanced synovial sarcoma.
Robin Jones • 15 Jun 2021
1:58
INVICTUS and INTRIGUE: investigating ripretinib in patients with advanced GIST
Robin Jones • 13 Apr 2022
1:52
DeFi trial: nirogacestat vs placebo for patients with progressing desmoid tumors
Robin Jones • 1 Nov 2022
0:57
SPEARHEAD-1: afamitresgene autoleucel in advanced synovial and myxoid liposarcoma
Robin Jones • 15 Jun 2021

Related Videos

1:36
Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS
Robin Jones • 26 Sep 2017
3:05
Elucidating the limitations and future prospects of the PerSARC model
Michiel Van De Sande • 9 May 2023
1:04
How has the trabectedin extended access program benefited sarcoma patients?
Robin Jones • 26 Sep 2017
2:06
The current state of drug development against sarcomas
Robin Jones • 26 Sep 2017
The content of VJOncology is intended for healthcare professionals